VEN+IDAC vs IDAC in AML

This study intends to use a randomized controlled design to compare the MRD-negativw rate and related efficacy and safety of venetoclax combined with intermediate-dose cytarabine (IDAC) versus IDAC in the consolidation treatment of patients with AML after remission, providing high-quality evidence-based medical evidence for optimizing post-remission consolidation therapy for AML and improving patients' prognosis.

NCT Number	NCT07537257
Lead Sponsor	Guangdong Second Provincial General Hospital Collaborators: Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, Guangzhou First People's Hospital, Dongguan People's Hospital, Zhongshan People's Hospital, Guangdong, China, Shunde Hospital, Sothen Medical University, Shenzhen Second People's Hospital
Conditions	AML (Acute Myelogenous Leukemia)
Enrollment	232 participants
Start Date	2026-04-01
Primary Completion	2027-04-01 (estimated)
Study Completion	2029-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-17